Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

615
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
615
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

805
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
805
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

565
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
565
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

580
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
580
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

561
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
561
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Movement disorders in GLUT1 deficiency syndrome: a systematic review of the literature.

Journal of neurology·2026
Same author

Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS.

ERJ open research·2026
Same author

One brain, one mind: A joint EPA-EAN leadership perspective on brain health.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance".

Clinical pharmacology and therapeutics·2026
Same author

Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas.

Rheumatology (Oxford, England)·2026
Same author

Palliative Care in Europe: Safeguarding Compassion Amidst Changing End-of-Life Policies and Expanding Access to Medically Assisted Dying Position Statement on behalf of the European Academy of Neurology, the European Federation of Neurological Associations and OneNeurology.

European journal of neurology·2026
Same journal

The Challenges of Scientific Publishing: An Editor-In-Chief's Perspective.

Fundamental & clinical pharmacology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Nov 3, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K

Gout and Levodopa: An unknown adverse effect?

Laura Quarteroni1, Romain Gastaldi2, Athan Baillet2,3

  • 1Pharmacy Unit, CHU of Grenoble Alpes, La Tronche, France.

Fundamental & Clinical Pharmacology
|June 1, 2021
PubMed
Summary
This summary is machine-generated.

Levodopa, a medication for Parkinson's disease (PD), may trigger gout flares in some patients. Analysis of global safety reports suggests a potential link between levodopa use and gout attacks.

Keywords:
Levodopacrystal arthropathiesdrug-induced rheumatic disease

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.1K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.7K

Related Experiment Videos

Last Updated: Nov 3, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.1K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.7K

Area of Science:

  • Neurology
  • Rheumatology
  • Pharmacovigilance

Background:

  • Parkinson's disease (PD) management often involves levodopa.
  • Gout is a form of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, and tenderness.

Observation:

  • A case study detailed a patient with PD experiencing recurrent gout flares after levodopa initiation and re-challenge.
  • A review of the World Health Organization's VigiBase® identified 43 cases of gout associated with N04BA drugs, with levodopa suspected in fifteen.

Findings:

  • Levodopa was suspected in 15 of 43 reported gout cases linked to N04BA drugs.
  • While some cases showed improvement after levodopa withdrawal or dose adjustment, others did not recover, and reintroduction of levodopa in the case study led to a gout relapse.

Implications:

  • This study suggests a potential association between levodopa and gout flares, warranting further investigation.
  • Clinicians should consider monitoring uric acid levels and potential gout development in patients initiating levodopa therapy.